Corcept Therapeutics (CORT)
Develops cortisol-modulating medicines for endocrine disease and cancer.
Something off on this page? Send us feedback.
Sells Korlym for endogenous Cushing's syndrome and Lifyorli, an ovarian-cancer therapy used with nab-paclitaxel. The commercial-stage business is built around cortisol modulation, with Korlym its commercial base and Lifyorli extending the platform into oncology.
Markets Korlym for endogenous Cushing's syndrome and an authorized generic, while Lifyorli is approved with nab-paclitaxel for specified platinum-resistant ovarian, fallopian-tube, and primary-peritoneal cancers.
The commercial-stage business centers on cortisol modulation, with additional clinical work in Cushing's syndrome, solid tumors, ALS, and liver disease. Korlym is marketed in the United States and remains the commercial base; Lifyorli extends the platform into oncology.
Generic mifepristone competition, Korlym patent litigation, and distinct FDA paths for relacorilant shape the business. Its hypercortisolism application received a Complete Response Letter, separate from Lifyorli's oncology approval.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 18, 2026 | Truist Financial | Target | Target: $50 | Target: $164 |
| Jul 30, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $95 | Target: $165 |
| Jul 29, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $100 | Target: $150 |
| Jul 27, 2026 | Wolfe Research | Downgrade | Target: $30 | Target: $50 |
| Jun 2, 2026 | H.C. Wainwright | Target | Target: $75 | Target: $95 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $308.2M · Total debt $9.4M · Total assets $888.7M · Shareholders' equity $705.8M
- Revenue
- $256.1M
- Operating income
- $41.3M
- Net income
- $42.1M
No dividends on record.
| Institutions | 77.27% | 83.52M shares | |
|---|---|---|---|
| 451 holders · as of Jun 30, 2026 | |||
| Insiders | 18.62% | 20.13M shares | |
| 11 holders · as of Sep 18, 2026 | |||
| Other | 4.11% | 4.44M shares | |
| remainder | |||
108.10M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 11.50% | 12.43M | as of Jun 30, 2026 |
Ingalls & Snyder LLCInstitution | 7.34% | 7.93M | as of Jun 30, 2026 |
Joseph K. Belanoff1Insiderdirector, officer: Chief Executive Officer | 6.03% | 6.82M | filed Jun 2, 2026 |
Patrick G. Enright2Insiderdirector | 5.94% | 6.42M | filed Mar 22, 2017 |
G. Leonard Jr Baker3,4Insiderdirector | 5.28% | 5.47M | filed Mar 19, 2026 |
- Joseph K. Belanoff's transaction reports restate only vehicles that traded; the 2025 ownership statement (6.82M) less the 306.8K net shares sold since is used instead.
- Patrick G. Enright's transaction reports restate only vehicles that traded; the 2017 ownership statement (6.42M) is used instead.
- G. Leonard Jr Baker's transaction reports restate only vehicles that traded; the 2022 ownership statement (5.47M) plus the 240.0K net shares acquired since is used instead.
- G. Leonard Jr Baker reports a block also reported by Charles Schwab Investment Management Inc; it is counted once, under Charles Schwab Investment Management Inc.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 16, 2026 | Roberto Wandenkolk Vieira | officer: President, Oncology | −296 | $100.82 |
| Sep 15, 2026 | James N. Wilson | director | −10,000 | $110.69 |
| Sep 14, 2026 | Joseph Douglas Lyon | officer: See Remarks | −10,000 | $113.49 |
| Sep 1, 2026 | Sean Maduck | officer: See Remarks | −25,000 | $114.43 |
| Sep 2, 2026 | Roberto Wandenkolk Vieira | officer: President, Oncology | −58,333 | $110.76 |
- Teva (ADR)
Generic mifepristone challenges Korlym in Cushing's syndrome
- Xeris Biopharma
Recorlev competes in medical treatment of hypercortisolism
- Merck
Keytruda regimen overlaps in platinum-resistant ovarian cancer
- AbbVie
Elahere overlaps in FRα-positive platinum-resistant ovarian cancer
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Corcept Therapeutics | $117.07 | +2.91% | $12.30B | 270.9 | 29.3 | 14.8 | +31.7% |
| Teva (ADR) | $39.24 | −2.05% | $46.66B | 66.8 | 14.0 | 2.7 | −0.8% |
| Xeris Biopharma | $8.76 | −0.47% | $1.52B | — | 47.0 | 4.5 | +27.2% |
| Merck | $151.59 | +1.39% | $369.24B | 119.6 | 17.6 | 5.6 | +5.1% |
| AbbVie | $265.35 | +0.33% | $467.37B | 74.5 | 17.5 | 7.3 | +10.2% |
| Median | 74.5 | 17.5 | 5.0 | +7.6% |